These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

113 related articles for article (PubMed ID: 7872083)

  • 21. Molecular regulation of urokinase-receptor gene expression as one potential concept for molecular staging and therapy.
    Allgayer H
    Recent Results Cancer Res; 2003; 162():15-30. PubMed ID: 12790318
    [TBL] [Abstract][Full Text] [Related]  

  • 22. [The clinical prospects for the study of the plasminogen activation system in breast cancer].
    Gershteĭn ES; Kushlinskiĭ NE
    Vestn Ross Akad Med Nauk; 1999; (8):58-61. PubMed ID: 10487126
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Role of urokinase plasminogen activator receptor in thrombospondin 1-mediated tumor cell invasion.
    Albo D; Berger DH; Rothman VL; Tuszynski GP
    J Surg Res; 1999 Apr; 82(2):331-8. PubMed ID: 10090848
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Plasminogen binding and activation at the breast cancer cell surface: the integral role of urokinase activity.
    Stillfried GE; Saunders DN; Ranson M
    Breast Cancer Res; 2007; 9(1):R14. PubMed ID: 17257442
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Plasminogen activator inhibitor-1 as a measure of vascular remodelling in breast cancer.
    Fox SB; Taylor M; Grøndahl-Hansen J; Kakolyris S; Gatter KC; Harris AL
    J Pathol; 2001 Sep; 195(2):236-43. PubMed ID: 11592104
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Immunohistochemical localization of urokinase-type plasminogen activator, type-1 plasminogen-activator inhibitor, urokinase receptor and alpha(2)-macroglobulin receptor in human breast carcinomas.
    Christensen L; Wiborg Simonsen AC; Heegaard CW; Moestrup SK; Andersen JA; Andreasen PA
    Int J Cancer; 1996 May; 66(4):441-52. PubMed ID: 8635858
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Urokinase-dependent proteolysis in cultured colon cancer is directed by its receptor.
    Hollas W; Boyd D
    Semin Thromb Hemost; 1991 Jul; 17(3):225-30. PubMed ID: 1665585
    [No Abstract]   [Full Text] [Related]  

  • 28. High tumor tissue concentration of urokinase plasminogen activator receptor is associated with good prognosis in patients with ovarian cancer.
    Borgfeldt C; Bendahl PO; Gustavsson B; Långström E; Fernö M; Willén R; Grenman S; Casslén B
    Int J Cancer; 2003 Nov; 107(4):658-65. PubMed ID: 14520707
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Detection of mRNAs for urokinase-type plasminogen activator, its receptor, and type 1 inhibitor in giant cell tumors of bone with in situ hybridization.
    Zheng MH; Fan Y; Panicker A; Smith A; Robertson T; Wysocki S; Robbins P; Papadimitriou JM; Wood DJ
    Am J Pathol; 1995 Dec; 147(6):1559-66. PubMed ID: 7495280
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Calcitonin inhibits invasion of breast cancer cells: involvement of urokinase-type plasminogen activator (uPA) and uPA receptor.
    Han B; Nakamura M; Zhou G; Ishii A; Nakamura A; Bai Y; Mori I; Kakudo K
    Int J Oncol; 2006 Apr; 28(4):807-14. PubMed ID: 16525628
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Effect of antisense inhibition of Urokinase receptor on malignancy.
    Ossowski L
    Curr Top Microbiol Immunol; 1996; 213 ( Pt 3)():101-12. PubMed ID: 8815000
    [No Abstract]   [Full Text] [Related]  

  • 32. Endothelial cells and normal breast epithelial cells enhance invasion of breast carcinoma cells by CXCR-4-dependent up-regulation of urokinase-type plasminogen activator receptor (uPAR, CD87) expression.
    Serratì S; Margheri F; Fibbi G; Di Cara G; Minafra L; Pucci-Minafra I; Liotta F; Annunziato F; Pucci M; Del Rosso M
    J Pathol; 2008 Apr; 214(5):545-54. PubMed ID: 18189329
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Expression of urokinase-type plasminogen activator receptor is correlated with metastases of lingual squamous cell carcinoma.
    Wang J; Guo F; Wei H; Dong J; Wu J
    Br J Oral Maxillofac Surg; 2006 Dec; 44(6):515-9. PubMed ID: 16356605
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Expression of urokinase-type plasminogen activator and its receptor in squamous cell carcinoma of the oral tongue.
    Serpa MS; Mafra RP; Queiroz SIML; Silva LPD; Souza LB; Pinto LP
    Braz Oral Res; 2018; 32():e93. PubMed ID: 30231175
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Engaged urokinase receptors enhance tumor breast cell migration and invasion by upregulating alpha(v)beta5 vitronectin receptor cell surface expression.
    Silvestri I; Longanesi Cattani I; Franco P; Pirozzi G; Botti G; Stoppelli MP; Carriero MV
    Int J Cancer; 2002 Dec; 102(6):562-71. PubMed ID: 12447996
    [TBL] [Abstract][Full Text] [Related]  

  • 36. The topology of plasminogen binding and activation on the surface of human breast cancer cells.
    Andronicos NM; Ranson M
    Br J Cancer; 2001 Sep; 85(6):909-16. PubMed ID: 11556845
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Tissue urokinase-type plasminogen activator receptor levels in breast cancer.
    Gong SJ; Rha SY; Chung HC; Yoo NC; Roh JK; Yang WI; Lee KS; Min JS; Kim BS; Chung HC
    Int J Mol Med; 2000 Sep; 6(3):301-5. PubMed ID: 10934293
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Plasminogen activator inhibitor type 1 in cytosolic tumor extracts predicts prognosis in low-risk breast cancer patients.
    Grøndahl-Hansen J; Christensen IJ; Briand P; Pappot H; Mouridsen HT; Blichert-Toft M; Danø K; Brünner N
    Clin Cancer Res; 1997 Feb; 3(2):233-9. PubMed ID: 9815678
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Tissue distribution of soluble and receptor-bound urokinase in human breast cancer using a panel of monoclonal antibodies.
    Carriero MV; Franco P; Del Vecchio S; Massa O; Botti G; D'Aiuto G; Stoppelli MP; Salvatore M
    Cancer Res; 1994 Oct; 54(20):5445-54. PubMed ID: 7923178
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Clinical relevance of urokinase-type plasminogen activator, its receptor, and its inhibitor type 1 in endometrial cancer.
    Tecimer C; Doering DL; Goldsmith LJ; Meyer JS; Abdulhay G; Wittliff JL
    Gynecol Oncol; 2001 Jan; 80(1):48-55. PubMed ID: 11136569
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 6.